# Edouard Guillet

> Edouard Guillet is a post-ipo debt investor at IPF Partners backing Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [IPF Partners](https://shizune.co/investors/profile/ipf-partners)
- Location: Geneva, Switzerland
- Total investments: 1
- Last investment: Aug 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/edouard-guillet-05a642/

Edouard Guillet is a post-ipo debt investor at IPF Partners in Geneva focused on Biotechnology and Pharmaceutical. Edouard Guillet is Partner of IPF Partners, leading alternative financing provider focused on the European healthcare sector. With 18 years of experience in the healthcare industry & consulting, Guillet is a former Business Unit head at Gilead Sciences and Manager at Medtronic and the Boston Consulting Group. He has an extensive experience inhealthcare product, project and general management and an MsC from HEC School of Management in Paris.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |
| Health Diagnostics | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Poxel | Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energyregulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC). |  | Post-IPO Debt | Aug 08, 2022 |  |

1 of 1 investments shown.

## About IPF Partners

VC Fund · Luxembourg, Luxembourg

IPF Partners is a alternative financing provider focused on the European healthcare sector. IPF invests directly in emerging, commercial-stage European pharma/biotech, medtech and diagnostics companies.

2 contacts available at IPF Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Edouard Guillet | Partner | https://shizune.co/investors/profile/edouard-guillet |
| Georges Ralli | Partner | https://shizune.co/investors/profile/georges-ralli |

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Edouard Guillet invest in?

Edouard Guillet invests primarily in Biotechnology, Pharmaceutical and Health Diagnostics startups, most often at Post-IPO Debt stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Edouard Guillet last invest?

The most recent investment recorded for Edouard Guillet closed in Aug 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co